1 completed, 1 recruiting. 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Ira Winer: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASk Questions in GYnecologic Oncology (ASQ-GYO) Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List - Ovarian Cancer, Endometrial Cancer | Not applicable | Completed | Ira Winer | 68 | 2024-04-04 | 2026-08-20 |
| ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer Akt/ERK Inhibitor ONC201, Paclitaxel, Questionnaire Administration - Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | Recruiting | Ira Winer | 62 | 2020-01-21 | 2026-06-17 |
Ovarian Neoplasms (2) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Gestational Trophoblastic Disease (1) · Uterine Cervical Neoplasms (1) · Vaginal Neoplasms (1) · Vulvar Neoplasms (1)
Esters (1) · Paclitaxel (1) · TIC10 compound (1) · Taxes (1)
United States (2)